Please provide your email address to receive an email when new articles are posted on . In children with pulmonary arterial hypertension, early initiation of IV or subcutaneous parenteral prostanoid ...
Following an approval by the institutional review board, we examined representative sections of 10 normal breast tissues from patients undergoing reduction mammoplasty and 89 invasive breast cancer ...
Prostanoids, lipid metabolites involved in many processes in our bodies, transmit signals between cells by binding to G protein–coupled receptors (GPCRs) on cell surfaces. Due to the receptors’ ...
Researchers from Idorsia Pharmaceuticals Ltd. presented the discovery of ACT-1002-4391, a novel dual antagonist of the prostanoid EP2 and EP4 receptors, which is being developed for the treatment of ...
Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the ...
A paper published in Nature Medicine has shown that the G protein-coupled prostanoid EP4 receptor might be a new target for immuno-inflammatory disorders. In summary, this paper revealed that EP2 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback